Videos

The associate staff member in the department of neurology at Cleveland Clinic provided background on a recently published phase 1 trial showing benefits of DBS for chonic poststroke motor rehabilitation. [WATCH TIME: 3 minutes]

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly talked about the "Think Talk Treat Migraine" program and the 3 vital actions for providers take to improve migraine care for their patients. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending August 19, 2023. [WATCH TIME: 4 minutes]

The headache specialist at the Hartford Healthcare Headache Center discussed findings from a study that revealed altered retinal vasculature in individuals with migraine with aura, indicating potential retinal biomarkers for disease progression. [WATCH TIME: 4 minutes]

The executive vice president of the National MS Society discussed the challenges with treating progressive forms of MS, and the accumulating neurodegeneration seen over time. [WATCH TIME: 4 minutes]

The senior vice president of research at Vaxxinity discussed recently published trial findings on a novel vaccine that targets Alzheimer disease and triggers the production of antibodies against toxic amyloid-ß peptides. [WATCH TIME: 9 minutes]

The associate professor at Yeshiva University and Albert Einstein College of Medicine discussed the significance of motivational interviewing as a means for providers to engage with their patients and the harmful impact of societal stereotypes on individuals with migraine. [WATCH TIME: 5 minutes]

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly discussed the complexities of migraine treatment, highlighting the need to address communication barriers between healthcare providers and patients. [WATCH TIME: 5 minutes]

The associate professor of pediatrics in neurology and epilepsy at Northwestern University Feinberg School of Medicine discussed the FDA-cleared phase 1/2 trial of an exon 50 skipping therapy to address the specific mutations causing Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]

The undergraduate program director at the University of South Carolina discussed the shift in teaching strategies for those in neurology and why more hands-on experience serves students better. [WATCH TIME: 5 minutes]

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the dilemma of stratifying patients with Parkinson disease based on various criteria and emphasized the need for a consensus on classification. [WATCH TIME: 3 minutes]

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly discussed the Think Talk Treat Migraine program which encourages both medical professionals and patients to identify migraine's effects. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending August 12, 2023. [WATCH TIME: 3 minutes]

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly talked about the impact of migraine on women and the importance of primary care in managing this widespread condition. [WATCH TIME: 4 minutes]

The professor of anesthesiology at Washington University in St. Louis provided perspective on the respect and approach that comes with conducting research in underserved or impoverished communities. [WATCH TIME: 4 minutes]

The director of movement disorders at the Banner Sun Health Research Institute talked about alternative approaches for treating essential tremor beyond medications, and developments in the diagnostic criteria for Lewy body disorders. [WATCH TIME: 5 minutes]

The associate professor of neurology at the Indiana University School of Medicine discussed the screening paradigm for Alzheimer disease, and the reluctancy to use new digital tools over traditional methods. [WATCH TIME: 6 minutes]

The professor of neurology and residency program director at MedStar Georgetown University Hospital spoke to the evolution of the utility of botulinumtoxins in the treatment of patients with Parkinson and other movement disorders. [WATCH TIME: 4 minutes]

Bruce Cree, MD, PhD, MAS, presents his final thoughts for clinicians on the safety, efficacy, and tolerability of sphinogine-1-phospate (S1P) receptor modulators in the treatment of multiple sclerosis (MS).

Bruce Cree, MD, PhD, MAS, discusses new data presented at the 2023 European Academy of Neurology (EAN) congress on BTK inhibitors, such as Tolebrutinib, evobrutinib, renibrutinib, and fenibrutinib. Dr Cree also highlights important safety information and adverse events identified in these studies.

Bruce Cree, MD, PhD, MAS, provides his clinical advice on managing treatment cessation of sphinogine-1-phospate (S1P) receptor modulators while preventing multiple sclerosis (MS) disease rebound.

Bruce Cree, MD, PhD, MAS, discusses how sphinogine-1-phospate (S1P) receptor modulators may suppress a patients immune system and key considerations clinicians should make in light of this.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed patient reluctance towards new treatments for Parkinson disease and the role of education in defining treatment expectations for patients. [WATCH TIME: 4 minutes]

Bruce Cree, MD, PhD, MAS, discusses the data of long-term studies on fingolimod and ponesimod in relapsing-remitting multiple sclerosis (RRMS) and siponimod in secondary-progressive multiple sclerosis (SPMS).

Bruce Cree, MD, PhD, MAS, reviews the results of the long-term efficacy and safety study of ozanimod, DAYBREAK, in relapsing-remitting multiple sclerosis (RRMS) published last year. Dr Cree also discusses two other safety studies presented at the 2023 European Academy of Neurology (EAN) congress.

Bruce Cree, MD, PhD, MAS, discusses key considerations when selecting one of the four FDA approved sphinogine-1-phospate (S1P) receptor modulators for multiple sclerosis (MS). Dr Cree also highlights a particular adverse event observed in the extension studies of these four S1P receptor modulators.

Bruce Cree, MD, PhD, MAS, discusses the pathophysiology of multiple sclerosis (MS) and how sphinogine-1-phospate (S1P) receptor modulators address the underlying causes. Dr Cree also discusses the differences between the four FDA approved drugs for MS: fingolimod, siponimod, ozanimod, and ponesimod.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the steps needed to improve treatment optimization in SMA, and the unanswered questions regarding the key biology of the disease.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the subgroup findings from the phase 4 NURTURE study of nusinersen (Spinraza; Biogen) in presymptomatic spinal muscular atrophy. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending August 5, 2023. [WATCH TIME: 4 minutes]